1305 related articles for article (PubMed ID: 30033047)
21. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
Wei L; Chintala S; Ciamporcero E; Ramakrishnan S; Elbanna M; Wang J; Hu Q; Glenn ST; Murakami M; Liu L; Gomez EC; Sun Y; Conroy J; Miles KM; Malathi K; Ramaiah S; Anbarasu A; Woloszynska-Read A; Johnson CS; Conroy J; Liu S; Morrison CD; Pili R
Oncotarget; 2016 Nov; 7(47):76374-76389. PubMed ID: 27823983
[TBL] [Abstract][Full Text] [Related]
22. Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder.
Garczyk S; Ortiz-Brüchle N; Schneider U; Lurje I; Guricova K; Gaisa NT; Lorsy E; Lindemann-Docter K; Heidenreich A; Knüchel R
Am J Pathol; 2020 Feb; 190(2):323-332. PubMed ID: 31734230
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer-An Extensive Multiregional Immunohistochemical Analysis.
Schallenberg S; Dragomir MP; Anders P; Ebner B; Volz Y; Eismann L; Rodler S; Casuscelli J; Buchner A; Klauschen F; Stief C; Horst D; Schulz GB
Eur Urol Focus; 2023 Sep; 9(5):788-798. PubMed ID: 37076398
[TBL] [Abstract][Full Text] [Related]
24. Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing.
Sasaki Y; Tamura M; Koyama R; Nakagaki T; Adachi Y; Tokino T
World J Gastroenterol; 2016 Feb; 22(7):2284-93. PubMed ID: 26900290
[TBL] [Abstract][Full Text] [Related]
25. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.
Sjödahl G; Eriksson P; Liedberg F; Höglund M
J Pathol; 2017 May; 242(1):113-125. PubMed ID: 28195647
[TBL] [Abstract][Full Text] [Related]
26. Genomic Characterization of Upper Tract Urothelial Carcinoma.
Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
[TBL] [Abstract][Full Text] [Related]
27. Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
Koll FJ; Döring C; Olah C; Szarvas T; Köllermann J; Hoeh B; Chun FK; Reis H; Wild PJ
BMC Cancer; 2023 Jun; 23(1):504. PubMed ID: 37270477
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: a paradigm for molecular subtyping of urothelial cell carcinoma of the bladder.
Adam RM; DeGraff DJ
Urol Oncol; 2015 Oct; 33(10):444-50. PubMed ID: 26254697
[TBL] [Abstract][Full Text] [Related]
29. DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma.
Conconi D; Panzeri E; Redaelli S; Bovo G; Volante M; Viganò P; Strada G; Dalprà L; Bentivegna A
BMC Res Notes; 2012 Oct; 5():607. PubMed ID: 23114535
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.
Shah RH; Scott SN; Brannon AR; Levine DA; Lin O; Berger MF
Cancer Cytopathol; 2015 May; 123(5):289-97. PubMed ID: 25655233
[TBL] [Abstract][Full Text] [Related]
31. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.
Choi W; Czerniak B; Ochoa A; Su X; Siefker-Radtke A; Dinney C; McConkey DJ
Nat Rev Urol; 2014 Jul; 11(7):400-10. PubMed ID: 24960601
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.
McConkey DJ; Choi W; Ochoa A; Siefker-Radtke A; Czerniak B; Dinney CP
Hematol Oncol Clin North Am; 2015 Apr; 29(2):377-94, x-xi. PubMed ID: 25836941
[TBL] [Abstract][Full Text] [Related]
33. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
34. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
[TBL] [Abstract][Full Text] [Related]
35. Next-generation RNA sequencing of archival formalin-fixed paraffin-embedded urothelial bladder cancer.
Liu Y; Noon AP; Aguiar Cabeza E; Shen J; Kuk C; Ilczynski C; Ni R; Sukhu B; Chan K; Barbosa-Morais NL; Hermanns T; Blencowe BJ; Azad A; van der Kwast TH; Catto JW; Zlotta AR; Wrana JL
Eur Urol; 2014 Dec; 66(6):982-6. PubMed ID: 25199720
[TBL] [Abstract][Full Text] [Related]
36. Lack of distinct molecular profile of Primary Dermal Melanoma.
Shaigany S; Tessier-Cloutier B; Busam KJ; Horst BA
Hum Pathol; 2020 Dec; 106():32-38. PubMed ID: 32946880
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of a NanoString BASE47 bladder cancer gene classifier.
Kardos J; Rose TL; Manocha U; Wobker SE; Damrauer JS; Bivalaqua TJ; Kates M; Moore KJ; Parker JS; Kim WY
PLoS One; 2020; 15(12):e0243935. PubMed ID: 33332422
[TBL] [Abstract][Full Text] [Related]
38. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.
Biton A; Bernard-Pierrot I; Lou Y; Krucker C; Chapeaublanc E; Rubio-Pérez C; López-Bigas N; Kamoun A; Neuzillet Y; Gestraud P; Grieco L; Rebouissou S; de Reyniès A; Benhamou S; Lebret T; Southgate J; Barillot E; Allory Y; Zinovyev A; Radvanyi F
Cell Rep; 2014 Nov; 9(4):1235-45. PubMed ID: 25456126
[TBL] [Abstract][Full Text] [Related]
39. Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies.
Fadlullah MZ; Chiang IK; Dionne KR; Yee PS; Gan CP; Sam KK; Tiong KH; Ng AK; Martin D; Lim KP; Kallarakkal TG; Mustafa WM; Lau SH; Abraham MT; Zain RB; Rahman ZA; Molinolo A; Patel V; Gutkind JS; Tan AC; Cheong SC
Oncotarget; 2016 May; 7(19):27802-18. PubMed ID: 27050151
[TBL] [Abstract][Full Text] [Related]
40. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
